PCR Rio Valves | DragonFly™ Shines in Rio, Connecting Global Expertise to Co-Create the Future of TEER

This conference specially invited the director of the Valve Center at the Scientific Research Institute of San Raffaele Hospital in Italy.Francesco MaisanoProfessorActing as the seminar moderator, leading the entire academic discussion with a forward-looking perspective. During the conference, Professor Marcelo Aguero from the Corrientes Cardiology Institute systematically shared the experience of the first clinical application of DragonFly™ in Argentina, elaborating on the procedural steps and key operational points of the TEER surgery in conjunction with the product's advantages. He pointed out,DragonFly™ adoptsFull-scale Control SystemCan significantly shorten the learning cycle for operators, aiding in the quick mastery of instrument operation. Meanwhile, it emphasizes its 45° internal...Free-angle locking with flexible central occlusion netThe design not only balances residual regurgitation and transvalvular pressure gradients but also takes into account both immediate tension and long-term stability, safely moving away from the "either too loose or too tight" single option, while improving surgical efficiency.

Cardiologist at Santiago Thoracic HospitalProfessor Manuel Duarte AriasShared the experience of 3 clinical applications of DragonFly™ in Chile. All surgeries achieved excellent results, with precise intraoperative instrument manipulation, stable and controllable grasping and release processes. Postoperatively, patients showed significant improvement in NYHA classification (all reaching Class I or II), a substantial decrease in BNP levels, and a marked reduction in mitral regurgitation. He pointed out that DragonFly™ has four types of clip models.Can provide a wide range of adaptable options for patients with different anatomical structures.

Alvaro Cunqueiro University Hospital of SpainProfessor Rodrigo Estevesz-LoureiroThis brings a deep analysis of the much-anticipated multi-center clinical research data in China.Comprehensively presented to the international academic community the 2-year long-term follow-up data of DragonFly™ in treating DMR patients and the 1-year data for FMR patients., sparking heated discussions among the experts present and providing solid evidence-based medical proof for the excellent efficacy of DragonFly™.

During the conference, Valgen Medtech's booth attracted significant attention due to the innovative design of DragonFly™.Unique advantages such as free-angle locking and scaled control system, attracting numerous international top surgeons to come for exchange and discussion, jointly talking about the future of mitral valve intervention.

This Rio trip, DragonFly™With its innovative design, robust clinical data, and increasingly rich international clinical application experience, it has sent a strong "Chinese voice" to the global structural heart disease field. With the original intention of benefiting lives, it provides excellent and accessible medical solutions for patients worldwide; with a firm belief in deep-rooted innovation, it comprehensively enhances the status and influence of Chinese medical devices in the global industrial chain.

Currently, Valgen Medtech DragonFly™After obtaining CE approval in Europe, it has been successively registered and approved in multiple countries across South America, the Middle East, Southeast Asia, and the CIS, and the global commercialization layout has been initiated. We believe in DragonFly.™Will bring better treatment options and a higher quality of life to more patients worldwide.